Background

IgG4-related disease (IgG4-RD) is a chronic systemic autoimmune disorder in which immune cells attack healthy organs, causing inflammation and fibrosis. Because it often simultaneously affects multiple organs such as the pancreas, salivary glands, and kidneys, the physical suffering experienced by patients can be severe. Until now, symptoms have been managed using potent immunosuppressive agents such as glucocorticoids. However, disease relapse has frequently occurred during the tapering of medication, and long-term use has led to systemic side effects such as diabetes and osteoporosis.

Recently, targeted therapies such as rituximab, which completely destroy B-cells, have been considered as alternatives. However, the complete elimination of B-cells weakens the immune system, increasing the risk of infections. Vaccine responses also decline, and serum immunoglobulin levels drop. This has created a demand for new drugs that can regulate B-cell activity without inducing cell death.

Key Findings

The results of the phase 3 INDIGO clinical trial, published in the New England Journal of Medicine (NEJM), demonstrate the strong efficacy of obexelimab. This global placebo-controlled trial involved 194 patients with active IgG4-RD. Patients underwent a process to completely discontinue steroids by week 8. Thereafter, participants were divided into a treatment group receiving subcutaneous injections of 250 mg of obexelimab weekly and a placebo group, and both were followed for 52 weeks.

The clinical trial results showed that the treatment group had a 56% reduction in disease relapse risk compared to the placebo group. The relapse rate in the obexelimab group was 26.8%, less than half of the 54.6% in the placebo group. The hazard ratio (HR), a measure of relapse risk, was recorded at 0.44, clearly supporting the drug's efficacy. The drug prevented the need for additional steroid use and contributed to maintaining complete remission. The frequency of adverse events was also similar to that of the placebo group, confirming its excellent tolerability.

Obexelimab's exceptional effectiveness stems from its unique mechanism of action. The drug is a bispecific antibody designed to simultaneously bind to CD19, a protein on the surface of B-cells, and FcγRIIb, an inhibitory receptor. This dual binding generates a strong control signal that blocks B-cell activation. Unlike conventional approaches that force B-cell death and create immune gaps, this drug maintains cell survival while only modulating abnormal activity.

Significance and Outlook

This study has been praised for opening a new therapeutic paradigm for autoimmune diseases without depleting B-cells. It particularly shows the potential to provide a steroid-free lifestyle for IgG4-RD patients who have long suffered from side effects due to lifelong medication. In clinical practice, it is being viewed as a promising alternative that could significantly improve treatment adherence and reduce drug-induced complications.

However, practical limitations must be considered for commercialization. The need for weekly subcutaneous injections is inconvenient, and the high cost of treatment remains a challenge. Additionally, further follow-up studies are required to clarify the subtle changes in the immune system that may occur with long-term drug use. Despite these constraints, the approach of managing autoimmune diseases without impairing antimicrobial immunity has sufficient potential to be extended to the treatment of various immune disorders.